Welcome to Revvity, a top destination for viral vector technologies and gene therapy solutions. Our gene delivery portfolio is specialised in the design, manufacturing and supply of custom vectors for discovery, gene, cell and immunotherapy applications, allowing us to support our clients through the entire cell and gene therapy value chain:
- Capsid evolution and design of clinical vectors to minimise vector dose and increase therapeutic success
- Process and development experience for optimised manufacturability
- Individual support and project planning with expert managers
- Manufacture of optimised viral vectors for late-stage preclinical applications
Design and development of multipurpose viral vectors
For the past 20 years, Revvity Gene Delivery has been at the forefront of synthesising, cloning, and producing viral vectors tailored to our clients’ designs. We provide comprehensive support for the efficient development of viral vectors for any application.
By considering various aspects and specific requirements of your vector, we can help you advance your development projects with the prerequisites for therapy development. Our expertise allows us to manufacture many adeno-associated virus (AAV), lentiviral, or adenoviral vectors.
Viral vector manufacturing and productivity optimisation
Revvity’s strong experience in manufacturing makes us one of the few viral vector manufacturers that has seen hundreds of AAV, lentiviral and adenoviral variants. We have a deep understanding of the production and purification processes which allow us to propose optimised processes to boost productivity and manufacturability of your viral vectors.
Our mission is to help therapeutic developers make gene therapies more accessible to patients. By developing more efficient viral vectors, we contribute to the gene and cell therapy field, allowing therapy developers to bring treatments to market with reduced manufacturing costs.
Adeno-associated virus (AAV) vector optimisation
Revvity’s AAV vector optimisation services are at the forefront of gene therapy advancements. Utilising directed evolution, peptide insertion and shuffled AAV libraries, we enhance vector specificity and efficiency. Our technologies support optimal gene expression and safety, making them ideal for developers creating therapeutic applications.
Manufacturing services for lentiviral vectors
Our lentiviral transduction technologies are designed to support CAR/TCR gene transfers and in vitro stem cell therapies. We offer comprehensive solutions that improve transduction efficiency and vector yield.
LentiBOOST™ Technology ‒ Enhanced lentiviral transduction efficiency
Our LentiBOOST technology is an effective lentiviral vector transduction enhancer. Designed to improve transduction efficiency, LentiBOOST enhances the effectiveness of lentiviral vectors in various applications, including gene therapy and CAR-T cell therapies.
• High-efficiency transduction: LentiBOOST increases the number of cells transduced for more effective gene delivery.
• Cost-effective solutions: By improving transduction efficiency and reducing the number of vectors required, LentiBOOST helps reduce overall costs in large-scale manufacturing processes.
• Broad applicability: Ideal for a wide range of applications, from basic research to clinical-grade cell therapy.
Commitment to quality and innovation
At Revvity, we are dedicated to pushing the boundaries of gene and cell therapy. Our gene delivery team of experts leverages advanced technologies to deliver quality, innovative solutions aimed to meet the evolving needs of our clients.
• Expertise: Decades of experience in viral vector engineering and gene therapy.
• Quality assurance: Rigorous testing processes to provide product reliability.
• Customer focus: Personalised solutions and support to achieve customer satisfaction.
About Revvity
The Revvity Gene Delivery team began in 2005 as Sirion-Biotech. Since then, we have rapidly evolved into a leading provider of viral vector technologies. Starting from our centre of excellence in Munich, Germany, we have expanded our operations globally, establishing a strong presence in the US and France.
We have successfully completed more than 2,000 projects to date, collaborating with more than 200 clients from academia and industry. Our commitment to innovation, quality and customer satisfaction has driven our growth and established us as a trusted collaborator in the field of gene and cell therapy.